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Extracellular vesicles (EVs), are important for intercellular communication in both physiolog-
ical and pathological processes. To explore the potential of cancer derived EVs as disease
biomarkers for diagnosis, monitoring, and treatment decision, it is necessary to thoroughly
characterize their biomolecular content. The aim of the study was to characterize and com-
pare the protein content of EVs derived from three different cancer cell lines in search of a
specific molecular signature, with emphasis on proteins related to the carcinogenic process.
Oral squamous cell carcinoma (OSCC), pancreatic ductal adenocarcinoma (PDAC) and
melanoma brain metastasis cell lines were cultured in CELLine AD1000 flasks. EVs were
isolated by ultrafiltration and size-exclusion chromatography and characterized. Next, the
isolated EVs underwent liquid chromatography-mass spectrometry (LC-MS) analysis for
protein identification. Functional enrichment analysis was performed for a more general
overview of the biological processes involved. More than 600 different proteins were identi-
fied in EVs from each particular cell line. Here, 14%, 10%, and 24% of the identified proteins
were unique in OSCC, PDAC, and melanoma vesicles, respectively. A specific protein pro-
file was discovered for each cell line, e.g., EGFR in OSCC, Muc5AC in PDAC, and FN1 in
melanoma vesicles. Nevertheless, 25% of all the identified proteins were common to all cell
lines. Functional enrichment analysis linked the proteins in each data set to biological pro-
cesses such as “biological adhesion”, “cell motility”, and “cellular component biogenesis”.
EV proteomics discovered cancer-specific protein profiles, with proteins involved in pro-
cesses promoting tumor progression. In addition, the biological processes associated to the
melanoma-derived EVs were distinct from the ones linked to the EVs isolated from OSCC
and PDAC. The malignancy specific biomolecular cues in EVs may have potential applica-
tions as diagnostic biomarkers and in therapy.
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1. Introduction
Extracellular vesicles (EVs) are released by cells into the extracellular space and are classified
according to their size and biogenesis [1, 2]. Accordingly, EVs with diameters of 30–100 nm and
of endosomal origin are defined as exosomes [2]. The EVs which originate by direct outward
budding of the cell membrane are named microvesicles (100–1000 nm) and apoptotic bodies
(>1000 nm) [2]. EVs are important players in cell-cell communication in health and disease [3]
due to their diverse content of biomolecules, such as lipids, nucleic acids, and proteins [4].
EVs are quite abundant in biofluids as they are continuously released by cells [2]. In some
diseases, e.g., cancer, the amount of EVs in the biofluids increases [5]. The EVs in the blood of
cancer patients are released both by normal and cancer cells, and their number is estimated to
be twice of that found in the blood of healthy individuals [6–8]. Oncogenes in cancer-derived
EVs can modulate normal host cells, e.g. fibroblasts and macrophages, as well as local cancer
cells and metastatic cells [9–11]. In this manner, tumor-derived EVs can contribute to and
maintain the Hallmarks of cancer, a panel of acquired abilities of malignant tumors such as
cancer cell proliferation, evasion of growth suppressors, resistance to cell death, migration,
and invasion as well as modulating normal cells to favor tumor progression by transforming
the microenvironment into a more permissive one [12–15].
Additionally, since EVs contain signaling molecules, they are considered be a potential
source of diagnostic biomarkers for the prediction of disease, as well as in disease monitoring
and treatment decision making [10, 16]. To explore the potential of cancer derived EVs as pos-
sible diagnostic and prognostic markers and to expand our understanding of their influence in
cell signaling in disease progression, there is a need to isolate EVs from the other components
in cell culture supernatant or biofluid of interest (e.g. blood, saliva, urine) [17]. One method
for EV separation is combining two size-based separation techniques (ultrafiltration (UF) and
size exclusion chromatography (SEC)). These use the size of EVs to separate them from other
components that are present in the biofluid or cell culture media. Once isolated, it is of great
value to characterize the EV content. Mass spectrometry (MS)-analysis allows for the identifi-
cation and characterization of proteins in EV samples. However, the enormous amount of
data produced by this technique can be quite extensive [18]. Therefore, to extract meaningful
information from the extensive list of proteins, Gene Ontology (GO) has become a useful
resource, by associating a GO term to each protein or group of proteins in the data set [18].
Overall, GO is a standardized language, or ontology, that describes the function of a gene or a
gene product (RNAs or proteins) in three key domains: biological processes, molecular func-
tions, and cellular components [18–20].
In this study, we characterized the protein content of small EVs (diameters under 200 nm),
most likely exosomes and small microvesicles. These were isolated by the combination of UF
and SEC from cell culture supernatant of three distinct cancer cell lines: oral squamous cell
carcinoma (OSCC), pancreatic ductal adenocarcinoma (PDAC), and melanoma, all with poor
prognosis [21, 22]. We aimed to provide information on and compare the protein content car-
ried by EVs from these different malignancies. Overall, we attempted to identify an EV specific
molecular signature characteristic of each cancer which could be explored for diagnostic work
and/or in the prediction of prognosis of these malignancies. In addition, we studied the protein
content of the EVs in relation to the carcinogenic processes known as Hallmarks of cancer.
2 Methods
2.1 Cell culture
Small EVs were isolated from the culture media of human oral squamous cell carcinoma (OSCC)
(PE/CA-PJ49/E10; ECACC, Salisbury, UK), pancreatic ductal adenocarcinoma (PDAC) (BxPC3,
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ATCC, Manassas, USA), and human melanoma brain metastasis (H3; a kind gift from Prof. F.
Thonsen, University of Bergen, Norway). The cells were cultured as previously described [23].
In order to reduce the amount of EVs from the FBS, all cell lines where progressively adapted
to Advanced media (Gibco, Life Techologies) supplemented with 1% exosome depleted FBS
(Gibco, Life Technologies). Briefly, E10, BxPC3, and H3 cells were cultured in complete, con-
ventional media (respectively: Iscove’s Modified Dulbecco’s medium (IMDM; SIGMA), Ros-
well Park Memorial Institute (RPMI; Gibco, Life Technologies), and Dulbecco’s Modified
Eagle Medium (DMEM; Gibco, Life Technologies), all supplemented with 10% FBS). Thereaf-
ter, we adapted the cells by sub-culturing them in increasing ratios of Advanced DMEM (E10
and H3) and Advanced RPMI (BxPC3) all supplemented with 1% exosome depleted FBS, 2
mM L-glutamine (Thermo Scientific), and 1X Antibiotic Antimycotic Solution (penicillin,
streptomycin, and amphotericin B (PSA), SIGMA). Sub-culturing was carried out during 8
weeks for the E10 and BxPC3 cell lines. Due to a lower proliferation rate of the H3 cells, sub-
culturing of this cell line was carried out for a period of 10 weeks. At this point the conven-
tional media had been completely replaced with the Advanced media. Adapted cells were
grown in CELLine AD1000 reactor flasks (Argos Technologies), designed for mass production
of adherent cells. Cells were kept at 37˚C in a 5% CO2 atmosphere incubator.
2.2 EV isolation
Cell culture supernatants were collected once a week. After collection of the cell culture super-
natant, the CELLine AD1000 flasks were washed with warm PBS. Cell culture supernatant and
PBS were then pooled. Samples were centrifuged at 4000g for 5 min at room temperature, to
remove cell debris and the supernatant was then centrifuged for another 45 min at 15000g,
20˚C. Next, 15 ml of the 15000g supernatant was concentrated by UF using Amicon-Ultra 15
Centrifugal Filter Units (Merck Milipore) with a 50 kDa molecular weight cut-off (MWCO),
to a final volume of 4 ml. Concentrates were loaded into 30 ml sepharose CL-2B (GE Health-
care Bio-Sciences AB) size-exclusion chromatography (SEC) columns. The concentrated cell
culture supernatants were eluted through the columns with the continuous addition of filtered
PBS. Eluates were collected by gravity in 20 fractions of 1 ml. For each fraction, protein quanti-
fication was determined by spectrophotometry (Absorbance 280nm) in a Nanodrop spectro-
photometer (Thermofisher).
Following protein quantification, the EV enriched fractions were identified and pooled.
Samples were characterized by nanoparticle tracking analysis (NTA), immunoaffinity capture
(Exosome Human CD9 Flow Detection Kit (Dynal1, Thermo-Fisher Scientific)), western blot
(WB) (anti-CD9 antibody (10626D, Invitrogen, Carlsbad, USA)) and transmission electron
microscopy (TEM), as described elsewhere [23]. Briefly, using NTA, the particle concentration
and their size were estimated. Samples were analyzed for the presence of classical exosome
markers by western blot Isolated EVs were also characterized by immunoaffinity capture for
the presence of CD9. Lastly, visualization of the isolated EVs was carried out by TEM.
2.3 Proteomics
Following characterization, proteomic analysis was carried out using a total of 20 μg of protein
for each of the preparations (n = 3 for each of the cell lines), as described in detail in (S1 File).
Briefly, each sample was precipitated and the EV proteins were digested by trypsin. The result-
ing peptides were analyzed on an Ultimate 3000 RSLCnano-UHPLC system connected to a Q
Exactive mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) equipped with a
nano-electrospray ion source. The peptide mass/spectra were compared to a reference data-
base (SwissProt database, Human) for peptide identification and the multiple identified
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peptides are assembled for protein identification. Protein identification and validation, includ-
ing statistical analysis were carried out using Scaffold_4.8.7 (Proteome Software Inc.) (See S1
File).
2.4 Data analysis
Validation of liquid chromatography-mass spectrometry (LC-MS)-based peptide and protein
identifications was carried out using Scaffold_4.9.0 (Proteome Software Inc., Portland, OR,
USA). Here protein threshold was set at 99.0% to ensure that only proteins with 99% of proba-
bility of being present were produced, and the minimum number of peptides was set to 2. Fur-
thermore, the peptide threshold was set at 95%, the minimum probability to determine if a
given spectrum identifies a peptide.
Data from the vesicles isolated from E10, BxPC3, and H3 cell culture supernatants were
analyzed and extracted individually from Scaffold. All datasets were screened and proteins that
were not present in all 3 replicates within a cell line were not included for further analysis.
Comparison of the proteins from the different cell lines was carried out using the Func-
tional Enrichment Analysis Tool (FunRich) (http://www.funrich.org). In addition, the pro-
teins identified in the preparations from E10, BxPC3, and H3 were compared with the
Vesiclepedia database (http://microvesicles.org), a web-based open source compendium of
biomolecules (proteins, RNAs, lipids, and metabolites) found across all classes of EVs from
published and unpublished studies [24]. Proteins from each dataset were ranked according to
their average spectral count (SC), a semi-quantitative measure of protein abundance [25]. The
top 20 proteins were extracted for a more detailed analysis. Furthermore, proteomes of the
EVs from E10, BxPC3 and H3 cell lines were screened for the presence of tumor related pro-
teins previously described in the literature, and their role in the acquisition of cancer charac-
teristics known as Hallmarks of cancer [26–33].
Analysis of the proteomics datasets of the isolated EVs from the different cell lines was car-
ried out using the Database for Annotation, Visualization and Integrated Discovery (DAVID)
Bioinformatics Resources 6.8. The proteins were classified according to their gene ontology
(GO) term and categorized into functional groups under the term “Biological processes”
(GOTERM_BP_FAT). Next, the GO terms were grouped into “Functional annotation clus-
ters”, where the terms are organized into groups based on the premise that genes with similar
annotation are functionally related to each other [34]. Functional annotation clusters were
ranked according to their enrichment score (ES), indicating the relative importance of each
cluster [34, 35]. GO terms, ES and statistical determinants (p-values and False Discovery Rate,
FDR) were calculated by the DAVID software.
3. Results
3.1 EV characterization
EVs derived from OSCC, PDAC, and melanoma brain metastasis cell lines were isolated from
the cell culture supernatant combining UF and SEC, and were characterized by NTA, WB,
immunoaffinity capture, and TEM (Fig 1). Average particle concentration, as determined by
NTA, was 1.82x1010, 3.14x1010, and 2.22x1010 particles/ml for E10, BxPC3, and H3, respec-
tively (Fig 1B). Immunoaffinity capture was also used to analyze the presence of CD9 in the
small EVs (Fig 1C). E10 and BxPC3 were found to be positive for this marker, while its expres-
sion was very low in the vesicles from H3. The EVs were examined for the detection of the
markers CD9, CD81, and CD63 by WB. Here only CD9 was detected (Fig 1D), and only in the
vesicles derived from the E10 and BxPC3 cell lines. Analysis by TEM showed the presence of
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EVs with diameters in the range of 60–140 nm, presenting a dark central area surrounded by a
lighter peripheral zone corresponding to the membrane of the small EVs (Fig 1E).
The EVs underwent liquid-chromatography mass-spectrometry (LC-MS) analysis for iden-
tification and characterization of their protein content.
3.2 Overview of EV protein content
Proteomic analysis of the vesicles isolated from cell culture supernatant from the three cell
lines identified 678 different proteins from the E10 derived EVs, 618 proteins from the BxPC3
derived EVs, and 762 proteins from H3 derived EVs (Fig 1A). Interestingly, 25% of all the pro-
teins identified were common to all cell lines. Additionally, 7–10% of the total proteins identi-
fied were shared by two cell lines. In contrast, 14%, 10%, and 24% proteins were unique in
E10, BxPC3, and H3 vesicles, respectively. Furthermore, most of the proteins in the vesicles
from the cell lines were already identified and registered in the Vesiclepedia database [36] (Fig
1B), with only a few exceptions (9 proteins in E10, 8 in BxPC3, and 11 in H3; S1 Table). In
addition, the 30 proteins most often identified in EVs according to Vesiclepedia, including the
vesicle markers CD9, HSPA8, and ENO1, were also found to be present in our preparations.
However, CD63 was detected only in the H3 vesicles (S2 Table).
3.3 Top 20 proteins of each cell line
The top 20 most highly expressed proteins in the EVs from each of the cell lines are listed in
Table 1 together with their known functions. Here, EVs from E10 were found to be enriched
in EGFR, ITGB4, NT5E, MYO1C, ATP1A1, and CTNNA1, while enriched proteins in the
Fig 1. Characterization of the small EVs isolated from the cell culture supernatant of the E10, BxPC3, and H3 cell lines. EVs were studied by protein
concentration measurements (A), NTA for particle quantification (B), immunoaffinity capture targeting CD9 (C), and Western blot for the detection of CD9 in
three sequential SEC fractions (20 μl per well) (D). Samples were negatively stained with 4% uranyl acetate (aqueous) for analysis by TEM (E). Data republished
from Guerreiro et al [23].
https://doi.org/10.1371/journal.pone.0238591.g001
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Table 1. The 20 most highly enriched proteins in the vesicles isolated from the E10, BxPC3, and H3 cell lines, ranked according to the average spectral count (SC).



















Integral component of basement
membranes; promotes
angiogenesis









Cancer cell invasion and
metastasis
EGFR (158) Promotes tumorigenesis and angiogenesis AGRN (160) Cellular proliferation, migration and
oncogenic signaling
FASN (162) Contributor to transformation
and tumorigenic potential;
cellular growth and proliferation
MYH9 (142) Cytoskeleton reorganization MUC5B
(135)
Promotes proliferation, migration and




ITGB4 (141) Tumor cell proliferation, migration and
survival; Regulation of keratinocyte polarity
and motility
PKM (135) Tumor cell proliferation and survival FN1 (137) Cell adhesion, cell motility,
wound healing, and





Thought to mediate the attachment,




FN1 (99) Cell adhesion, cell motility, wound healing,
and maintenance of cell shape
MVP (108) Drug resistance; cell survival and
malignant progression
CLTC (129) Endocytosis and mitosis
MSN (93) Cell adhesion and mobility ACTG1 (99) Cell motility ACTG1
(115)
Cell motility
LAMA5 (92) May mediate attachment, migration and
organization of cells

















Promotes cancer progression APOE (102) Lipid transport; promotes cancer
cell proliferation and survival
CLTC (89) Endocytosis and mitosis PTGFRN
(84)
Promotion of metastasis MYH10
(101)
Cell migration
NT5E (89) Promoter tumor growth LGALS3BP
(82)
Promotes cell proliferation and
inhibits apoptosis in cancer cells;
promotes angiogenesis
LAMA1 (99) May mediate attachment,




Promotion of metastasis MUC16 (80) Promotes cell growth, tumorigenesis
and metastasis
CSPG4 (96) Migration; epithelial to
mesenchymal transition




Extracellular vesicle marker FASN (72) Contributor to transformation and
tumorogenic potential; cellular growth
and proliferation
MYH9 (90) Cytoskeleton reorganization
MYO1C
(76)
Angiogenesis, glucose uptake and progression
of cell cycle
PLEC (71) Involved in tumor growth PYGB (89) Drives glycogenolysis in brain
LGALS3BP
(73)
Promotes cell proliferation and angiogenesis;
inhibits apoptosis in cancer cells
EEF2 (69) Promotion of cancer cell growth HSP90AB1
(88)
Molecular chaperone
ATPA1 (69) Creates the electrochemical gradient of
sodium and potassium ions, providing the
energy for active transport of various
nutrients
ITGB4 (65) Tumor cell proliferation, migration
and survival Regulation of





PLOS ONE Cancer-specific protein profiles in extracellular vesicles
PLOS ONE | https://doi.org/10.1371/journal.pone.0238591 September 4, 2020 6 / 20
BxPC3 vesicles were mucins (MUC5AC, MUC5B, MUC16, and MUC2), MVP, COL7A1,
PGK1, PLEC, and EEF2. In addition, the most enriched proteins in the EVs from the H3
cell line were HMCN1, HSP8A, APOE, LAMA1, HSP90AB1, CSPG4, PYGB, MYH10, and
LAMB1. All the vesicles were also found to be enriched in HSPG2, GAPDH, CLTC, ACTG1,
PKM, AGRN, and PTGFRN.
Thus, despite the presence of common proteins, the EVs isolated from the different cell
lines showed an individual profile.
3.4 EV protein content related to the Hallmarks of cancer
When the proteins in our datasets were analyzed in view of the Hallmarks of cancer, we identi-
fied proteins with roles in the processes of angiogenesis, inflammation, cell proliferation,
migration, immunity, and cell adhesion (Table 2).
The EVs from each of the cell lines demonstrated varied protein profiles related to these
processes. For example, the panels of proteins associated with cell proliferation, migration,
and adhesion were fairly extensive for both E10 and BxPC3. Of note is the presence of several
members of the integrin family (IT), associated with cell proliferation, migration, and adhe-
sion, such as ITGA2, ITGA3, ITGA6, ITGA5, ITGB1, and ITGB4 in the EVs derived from E10
and BxPC3. In contrast, only half of the cell proliferation-related proteins were found in EVs
from the H3 cell line, most of them poorly expressed (with SC below 10). The number of pro-
teins related to adhesion were also reduced in the H3 derived EVs. Here ITGB1, ITGA3, and
ITGA2 were found in the vesicles from H3, the latter with fairly low SC.
Overall, the protein content of the EVs isolated from the different cell lines carry signals
that promote cancer traits. However, the EVs from the H3 melanoma cell line have a more dis-
tinct protein signature than the other two, with respect to both the type of proteins as well as
their amount present.
3.5 EV protein content in relation to biological processes
To better understand the roles and relationships of the proteins in the isolated EVs, Gene
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subunit alpha-1 (ATP1A1); Catenin alpha-1 (CTNNA1); Mucin-5B (MUC5B); Major vault protein (MVP); Collagen alpha-1(VII) chain (COL7A1); Mucin-16
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Cytoplasmic dynein 1 heavy chain 1 (DYNC1H1); Heat shock cognate 71 kDa protein (HSP8A); Apolipoprotein E (APOE); Laminin subunit alpha-1 (LAMA1); Heat
shock protein HSP 90-beta (HSP90AB1); Chondroitin sulfate proteoglycan 4 (CSPG4); Glycogen phosphorylase, brain form (PYGH); Myosin-10 (MYH10); Laminin
subunit beta-1 (LAMB1)
https://doi.org/10.1371/journal.pone.0238591.t001
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Table 2. EVs isolated from cell culture supernatants of E10, BxPC3, and H3 contain proteins shown to modulate tumor cells and metastatic environment [26–33]
(for more detailed information on protein function and average spectral counts (SC), see S3 Table).
Role \ Cell line E10 (SC) BxPC3 (SC) H3 (SC)
Angiogenesis ITGB1 (68) MFEG8 (47) MFEG8 (61)
TNC (63) ITGB1 (19) TNC (51)
ICAM (55) ICAM (9) ITGB1 (25)
MFEG8 (47) ICAM (2)
Inflammation S100A9 (15) S100A9 (9) MIF (8)
MIF (14) MIF (7)
Proliferation EGFR (158) ITGB4 (65) CSPG4 (96)
ITGB4 (141) Muc4 (43) ITGA3 (18)
ITGA6 (66) Muc1 (35) CDC42 (8)
ITGA3 (59) ITGA6 (32) TIMP1 (4)
ITGA2 (57) EGFR (26) ITGA2 (2)
CSPG4 (34) ITGA3 (16) EGFR (2)
ITGA5 (31) ITGA2 (15)
CDC42 (15) CDC42 (14)
ADAM10 (13) TIMP1 (12)
Muc1 (11) S100A14 (10)
S100A14 (9) ADAM10 (6)
TIMP1 (9) ITGA5 (6)
Muc4 (5) CSPG4 (4)
Migration ITGB4 (141) ITGB4 (65) FN1 (137)
FN1 (99) ITGA6 (32) CSPG4 (96)
ITGB1 (68) ITGB1 (19) TNC (51)
ITGA6 (66) ITGA3 (16) VIM (47)
TNC (63) ITGA2 (15) LOXL3 (40)
ITGA3 (59) CDC42 (14) ITGB1 (25)
ITGA2 (57) FN1 (12) ITGA3 (18)
CSPG4 (34) LOXL2 (7) CDC42 (8)
ITGA5 (31) ITGA5 (6) ITGA2 (2)
LOXL2 (20) ADAM10 (6)
CDC42 (15) CSPG4 (4)
ADAM10 (13)
Immunity Muc5AC (90) Muc5AC (407) PMEL (26)
LEG1 (23) LEG1 (8) LEG1 (17)
Muc5AC (14)
Adhesion ITGB4 (141) ITGB4 (65) FN1 (137)
FN1 (99) TINAGL1 (58) ITGB1 (25)
ITGB1 (68) THBS1 (53) ITGA3 (18)
ITGA6 (66) ITGA6 (32) Muc18 (14)
ITGA3 (59) ITGB1 (19) TINAGL1 (2)
ITGA2 (57) CD166 (17) ITGA2 (2)
TINAGL1 (53) ITGA3 (16)
ITGA5 (31) ITGA2 (15)
ALCAM (22) FN1 (12)
THBS1 (15) ITGA5 (6)
Muc18 (4) FN1 (12)
Integrin beta-1 (ITGB1), Tenascin C (TNC), S-100 calcium binding protein A9 (S100A9), Integrin, alpha 2 (ITGA2), Integrin, alpha 3 (ITGA3), Integrin, alpha 5
(ITGA5), Integrin, alpha 6 (ITGA6), Integrin, beta 4 (ITGB4), Mucin 1 (Muc1), Mucin 4 (Muc4), S-100 calcium binding protein A14 (S100A14), S-100 calcium
binding protein A10 (ADAM10), Epidermal growth factor receptor (EGFR), Cell division control protein 42 homolog (CDC42), Chondroitin sulfate proteoglycan 4
(CSPG4), Metalloproteinase inhibitor 1 (TIMP1), Fibronectin (FN1), Lysyl oxidase homolog 2 (LOXL2), Lysyl oxidase homolog 3 (LOXL3), Vimentin (VIM), Mucin
5AC (Muc5AC), Melanocyte protein (PMEL), Mucin 18 (Muc18), Macrophage migration inhibitory factor (MIF), Intercellular adhesion molecule (ICAM),
Thrombospondin-1 (THBS1), CD166 antigen (ALCAM), Galectin 1 (LEG1), Tubulointerstitial nephritis antigen-like (TINAGL1), Tissue factor (F3), Lactadhering
(MFGE8)
https://doi.org/10.1371/journal.pone.0238591.t002
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In the dataset of proteins identified in the E10 vesicles, the 8 most enriched biological pro-
cesses in the functional annotation cluster analysis (Fig 3A) included biological adhesion, cell
motility, interspecies interaction between organisms, cellular localization, cellular component
organization, response to wounding, cellular component biogenesis, and interaction with host.
Interestingly, the same biological processes were identified in the vesicles isolated from BxPC3
(Fig 3B). However, these presented lower enrichment scores than the E10 vesicles. The protein
datasets from the EVs isolated from the H3 cell culture supernatant were distinct from the
ones of E10 and BxPC3. In H3 (Fig 3C), enriched biological processes included interspecies
interaction between organisms, biological adhesion, cellular component biogenesis, RNA met-
abolic process and protein localization, cellular component organization, cellular response to
chemical stimulus, organic acid metabolic process, and extracellular structure organization.
4. Discussion
Extracellular vesicles carry complex biomolecular cues and thus, play an important role in the
communication between cells. In this study we analyzed and categorized the protein content
from EVs derived from oral squamous cell carcinoma (OSCC), pancreatic ductal adenocarci-
noma (PDAC), and melanoma brain metastasis cell lines (E10, BxPC3, and H3, respectively),
all cancers with poor prognosis for the patient. Isolation of the EVs from the cell culture super-
natants, prior to proteomic analysis, was carried out combining UF and SEC. The EVs were
characterized by NTA, WB, immunoaffinity capture, and TEM.
4.1 Overview of protein content
Characterization of the protein content of the isolated vesicles by LC-MS identified a similar
number of proteins for all preparations: 678 proteins for E10, 618 for BxPC3, and 762 for H3
(Fig 2A). When comparing the contents of proteins in the different preparations, a number of
proteins were found to be unique for each of the cell lines (14%, 10%, and 24% of identified
proteins in E10, BxPC3, and melanoma brain metastasis, respectively), suggesting that they
have distinct EV profiles. Analysis of the protein datasets produced from the EVs isolated from
E10, BxPC3, and H3 was carried out by comparing them with the Vesiclepedia database, a
Fig 2. A: Venn diagrams comparing the lists of all the proteins identified in the small EVs derived from OSCC (yellow), PDAC (blue), and
melanoma cells (red). B: All proteins from the different datasets were compared with the proteins listed in the Vesiclepedia database
(green).
https://doi.org/10.1371/journal.pone.0238591.g002
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Fig 3. Gene Ontology (GO) functional enrichment analysis of the biological processes (GOTERM_BP_FAT) of
the identified proteins in the EVs isolated from the cell culture supernatant of E10 (A), BxPC3 (B), and H3 (C).
Biological processes for each cell line were ranked according to their enrichment score, revealing which processes were
more relevant within each data set.
https://doi.org/10.1371/journal.pone.0238591.g003
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web-based directory of biomolecules (proteins, lipids, RNAs, and metabolites) identified in
different classes of EVs [24]. Vesiclepedia is maintained by continuous contribution of the
research community as well as manually curated data from published research [24, 36]. Here
we found that most of the proteins in the EVs from the different cell lines had previously been
reported (Fig 2B). However, the proteins in our samples not yet described in the Vesiclepedia
database (S1 Table) were found to be involved in processes such as cell adhesion, apoptosis,
regulation of exocytosis, and regulation of vesicular trafficking process. We further investi-
gated the abundance of these proteins in our samples using spectral count (SC), a semi-quanti-
tative measure of protein abundance in proteomic studies [25]. Here we found that the panel
of proteins not described previously presented low SCs, most of them SC<5. The work from
Lundgren et al., indicates that SC of less than five is unrealiable in studies with a small number
of replicates [25, 38, 39]. Thus, it is not clear if the absence of these proteins from the database
is due to no previous detection or to a low expression level. The 30 most frequently identified
proteins in EVs, as reported in Vesiclepedia, were then scrutinized in our dataset (S2 Table).
The proteins indexed in the Vesiclepedia list were found to be present in the EV samples from
E10, BxPC3 and H3 with the exception of CD63. The reason for the abscence of CD63 in our
samples is not clear and should be evaluated in future studies. This is a common extracellular
vesicle marker, and its presence has been previously reported in the EVs derived from BxPC3,
a cell line used in this study [40]. Nevertheless, CD63 positive vesicles have been described to
increase in response to stress [41]. The gradual modification of culture media used in the pres-
ent study, from the conventional media, supplemented with 10% FBS to the Advanced media,
might have lowered the cellular stress, and, therefore, reduced the amount of CD63. Further-
more, the culture conditions may also influence the CD63 levels. Indeed, it has been reported
that the presence of CD63 in vesicles derived from different colorectal cancer cell lines
depended on whether the cell growth occurred in a 2D versus 3D culture system [42].
4.2 The most abundant proteins in EVs isolated from each cell line
The proteins identified in the EVs of each cell line were ranked according to their average SC
for further analysis. Due to the large datasets for each of the cell lines, the top 20 most abun-
dant proteins were extracted (Table 1). A characteristic profile began to emerge for each of the
cell lines. In the vesicles isolated from E10, EGFR and ITGB4 were found among the top 20.
These proteins are known to have relevant roles in the development of OSCC [43]. EGFR is
involved in the acquisition of self-sufficient growth-stimulatory signaling, while ITGB4 pro-
motes the tumor ability for invasion and metastasis [43]. In BxPC3, the presence of several
types of mucins (MUC5AC, MUC5B, and MUC16) reflected what is described for pancreatic
tumors, which are known to overexpress these proteins [44]. For example, while absent in
healthy pancreatic tissue, expression levels of MUC16 increase in moderately to poorly differ-
entiated cancers, as is the case of the BxPC3 cell line used [44, 45]. The roles mucins hold in
the progression of pancreatic cancer include regulation of the detachment of the cells from the
primary tumor, invasion, and enhancement of the survival of detached cells [46–50]. In addi-
tion, these molecules also promote adhesion at metastatic sites [50–52]. Interestingly, MUC2
was found in our material. This is a tumor suppressor protein that is down regulated in pan-
creatic cancer [53]. Its presence among the proteins identified in the EVs derived from the
BxPC3 cell line can be explained by the fact that the cells themselves of this particular cell line
expresses MUC2 [54, 55]. For the top 20 highly expressed proteins in the EVs isolated from
the H3 cell line, LAMA1 and LAMB1, as well as CSPG4, stand out. Here, LAMA1 and LAMB1
have been identified as potential markers for cutaneous melanoma metastasis as these proteins
are involved in the modulation of cell adhesion and migration [37, 56, 57]. Also implicated in
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those latter processes is CSPG4 [37]. Furthermore, CSPG4 is involved in the activation of sur-
vival and growth pathways [58–60]. In addition to the proteins that are characteristic for each
particular cell line, the proteomic results also identified proteins shared by all the cell lines.
Those proteins were HSPG2, GAPDH, CLTC, ACTG1, PKM, AGRN, and PTGFRN. The spe-
cific role of HSPG2 and AGRN in EVs is not yet clear although they are known to be compo-
nents of the extracellular matrix (ECM), the molecular scaffold for tissue organization [37, 61].
Together, this could support the hypothesis that EVs play a functional and structural role in
ECM by participating in matrix organization by regulating cell migration or establishing
molecular networks within the ECM [62]. In addition, GAPDH, a so-called housekeeping pro-
tein that is often identified in the proteome of EVs, does not have a clear role in EVs. It has
been hypothesized that the presence of this protein, as well as other glycolytic enzymes, is
related to the maintenance of the EVs’ own energy that may be required for the uptake of can-
cer derived EVs by cells in the tumor microenvironment [63]. The remaining proteins are
involved in the maintenance of the membrane structure (ACTG1 and PTGFRN), the uptake
of EVs by endocytosis (CLTC), and the release of exosomes (PKM), in particular from cancer
cells [64–67].
In summary, our results highlight that the EVs isolated from each of the different cancer
cell lines have distinct protein profiles. Cell line-specific profiles already begins to emerge
when comparing the 20 most adundant proteins. Here, proteins that seem to provide tumors
with signals that promote its progression are found among EV-related proteins. These EV
related proteins are present in the datasets from all three cell lines.
4.3 Survey of EV protein contribution to cancer characteristics
The panel of proteins detected in the EVs from OSCC, PDAC, and melanoma cell lines (E10,
BxPC3, and H3, respectively) indicates that these vesicles can play roles in angiogenesis,
inflammation, proliferation, migration, as well as in modulation of immunity, all representing
Hallmarks of cancer. Within this selection of proteins (Table 2), there were noticeable differ-
ences among the cell lines. For example, there were more proteins associated with cell prolifer-
ation in E10 and BxPC3 compared to H3. This can be due to the proliferative characteristics
of each of the cell lines, with E10 presenting the highest growth rate and H3 the lowest. In
addition, although EVs from the three cell lines expressed many of the same proteins, their
amounts differed, as demonstrated by EGFR, Muc5AC, and FN1. EGFR was quite abundant
in the EVs from the E10 cell line, but its expression levels were at a much reduced level in
BxPC3. EGFR levels in H3 were barely detectable. The expression levels of EGFR in the E10
derived EVs may reflect the high expression of EGFR in OSCC tissue, as shown by immuno-
histochemistry (IHC), and its abundance in the saliva of OSCC patients, compared to controls
[68, 69]. EGFR has been detected by IHC in PDAC tissues as well as in the EVs derived from
PDAC cell lines, including BxPC3 [70, 71]. Studies on the transport of EGFR by tumor derived
EVs revealed that the transported EGFR will localize in the membrane of the recipient cells,
thus preparing distant sites for metastasis [72]. The presence of EGFR in the E10 and BxPC3
derived EVs may suggest that the same mechanism is at play with the exchange of growth fac-
tor receptors between the cells of the primary tumors, as well as between the tumor cells and
other cells in the tumor microenvironment and even cells in distant sites. The significance of
the difference we found in EGFR expression levels in the E10 and BxPC3 derived EVs needs to
be further investigated. The very low expression levels of EGFR in the H3 derived EVs could
be in line with what has been described in other studies where the presence of EGFR appears
to only be associated with a subset of melanomas [73]. It has also been observed that EGFR
expression in different melanoma cell lines and their EVs may vary [74].
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In contrast, Muc5AC was found to be highly enriched in the BxPC3 derived EVs, while
present in much lower amounts in the EVs from the other two cell lines. Muc5AC is a protein
that stimulates angiogenesis in PDAC and might also suppress the immune response towards
the tumor [75]. In patients, Muc5AC is known to be up-regulated in PDAC tissues as well as
in blood [76]. In this manner, our findings are in line with these previous studies. We could
not find published work describing the expression of this protein in OSCC and melanoma.
However, other members of the Muc family, Muc1 and Muc4, are associated with high aggres-
siveness of OSCC [77, 78].
Lastly, FN1 was abundant in the H3 derived EVs but detected in a smaller amount in the
E10 derived EVs. Furthermore, a dramatic drop in the FN1 content was found in the BxPC3
derived EVs. FN1 plays a role in cell adhesion, migration, and differentiation [32]. Further-
more, FN1 is highly expressed both in metastatic melanoma and OSCC cells [79, 80]. The
expression levels of FN1 in H3 and E10 derived EVs reflect those results. H3 is a cell line estab-
lished from a melanoma brain metastasis and E10 from a primary OSCC. In contrast to our
results, analysis of FN1 by IHC in PDAC tissues has demonstrated that this protein is abun-
dant in the tumor microenvironment [81]. Whether the very low amount of FN1 in our
BxPC3 derived EVs could be due to a selective protein loading into the EVs requires further
investigation.
Differences among the cell lines were also noticeable regarding members of the integrin
family. The members of this family of cell adhesion receptors are relevant in cancer processes
such as cell migration and invasion [82, 83]. In this study, a higher number of different integ-
rins was detected in the EVs derived from E10 and BxPC3 cell lines, in comparison to H3. The
low number of integrin members in the H3 derived EVs may be due to the cell line being gen-
erated from a melanoma brain metastasis. According to Hoshino et al the levels of integrin
expression in exosomes derived from melanoma brain metastasis are down regulated [84].
Moreover, proteins identified in our datasets were also detected in studies on biofluids from
OSCC, PDAC and melanoma patients. Some proteins present in the OSCC cell line derived
EVs in the present study were identified by Winck et al in saliva from OSCC patients (e.g.,
complement C3) [85]. Similarly, EVs derived from the PDAC and melanoma cell lines
included proteins (e.g., ALCAM and galectin-3, respectively) previously reported to be up-reg-
ulated in the serum of patients with PDAC and melanoma, respectively [86, 87]. This is an
interesting finding and suggests a benefit of parallel studies on cancer cell lines and saliva/
serum from cancer patients. This approach might contribute to the identification of possible
prognostic markers in saliva/serum of patients.
Overall, the EV content reflects the characteristics of each cell line. Additionally, the cell
line specific EV protein combinations point to the cellular phenotypical characteristics
described as Hallmarks of cancer. Furthermore, the proteins identified have been detected in
clinical cancer tissues in other studies, indicating that these may be relevant as diagnostic bio-
markers for these cancers.
4.4 Potential roles of EV proteins in relation to biological processes
Functional enrichment analysis was performed using DAVID annotation clustering. Here, we
identified the most enriched biological processes regulated by the hundreds of proteins identi-
fied in the EVs from each cell line (Fig 3). We found that the biological processes linked to the
H3 derived EVs were quite different from the ones associated with either E10 or BxPC3. The
most enriched biological processes unique for the H3 derived EVs were “RNA metabolic pro-
cesses and protein localization”, “cellular response to chemical stimulus”, “organic acid meta-
bolic process”, and “extracellular structure organization”. In contrast, “cell motility”, “cellular
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localization”, “response to wounding”, and “interaction with host” were the processes enriched
in E10 and BxPC3. Nevertheless, several of these biological processes are found to be associated
with cancer. For example, in H3 the “RNA metabolic processes and protein localization” and
“cellular response to stimulus” highlight a possible dysregulation of RNA processing which
may drive tumor progression [88]. “Cell motility” and “response to wounding” in E10 and
BxPC3 are important for cancer cell invasion of surrounding tissues and in establishing metas-
tasis [89, 90]. Whether the differences observed between H3 and E10/BxPC3 are a conse-
quence of the first being a cell line derived from a metastasized melanoma, while both E10 and
BxPC3 are derived from primary tumors, is not clear. However, there is evidence that a metas-
tasis possesses a gene expression program distinct from the primary tumor that have allowed
for the cancer cells to disseminate [91], which in turn may be reflected in the EV signaling.
The EVs derived from the three cancer cell lines also had some biological processes in com-
mon. “Interspecies interaction between organisms”, related to viral reproduction is one exam-
ple. This process reflects the similarity of EVs and viruses even though EV biogenesis is a
naturally occurring biological process while viruses hijack the cellular machinery for its propa-
gation [92]. In addition, all three cell lines had in common the biological processes of “cellular
component organization” and “cellular component biogenesis”, which are related to produc-
tion, assembly, and localization of elements of a cell.
Together, these findings reveal that the EVs analyzed in our study contain proteins that can
regulate biological processes towards a cancer phenotype, in a manner that is characteristic for
each of the cell lines.
5. Concluding remarks
In conclusion, in the present study we used LC-MS to characterize the protein content of small
EVs derived from OSCC, PDAC, and melanoma brain metastasis cell lines. More than 600
proteins were identified in the EVs of each cell line. Analysis of the datasets revealed cell-spe-
cific protein panels. In short, EVs derived from E10 had a high expression of EGFR, ITGB4,
and NT5E, the EVs isolated from BxPC3 were enriched in mucins (MUC5A, MUC5B,
MUC16, and MUC2), and the most abundant proteins in the EVs from the H3 cell line
included HMCN1, HSP8A, and APOE. Furthermore, screening of the protein datasets for
proteins involved in the Hallmarks of cancer also exposed cell-specific protein panels. Here,
proteins associated with the promotion of processes such as angiogenesis, proliferation, migra-
tion, or adhesion were found to be present in the EVs derived from all three cell lines. This is
relevant due to the role of EVs in the modulation of the cells in the tumor microenvironment
(e.g. fibroblasts, macrophages and the cancer cells themselves) into a more permissive setting
for tumor progression. The list of proteins involved, for example, in cell proliferation was
quite extensive in E10 and BxPC3 in comparison to H3 where only half of the proteins were
found and most of them poorly expressed. Functional enrichment analysis by gene ontology
(GO) was carried out to extract a broader biological significance. Here, processes such as “bio-
logical adhesion”, “cell motility”, and “cellular component biogenesis”, all associated with
aspects of cancer, were found. However, the processes identified from the proteins from the
H3 derived EVs were distinct from the ones in the datasets from E10 and BxPC3, revealing an
underlying difference between the cell lines. This study focuses on the protein content of small
EVs, and does not explore other classes of biomolecules such as RNAs. Nevertheless, the pro-
tein lists generated and analyzed here may provide important information regarding the com-
plex biomolecular cues EVs carry. In a clinical setting, biofluids from cancer patients will
include a higher number of cancer-derived EVs in addition to non-cancer-related EVs. This
will complicate the collection and examination of spacific caner-derived EVs. Hence, we
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believe it is important to start with a broad analytical approach that may assist in pinpointing
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